[go: up one dir, main page]

PE20060074A1 - Derivados de (indol-3-il)-heterociclos - Google Patents

Derivados de (indol-3-il)-heterociclos

Info

Publication number
PE20060074A1
PE20060074A1 PE2005000245A PE2005000245A PE20060074A1 PE 20060074 A1 PE20060074 A1 PE 20060074A1 PE 2005000245 A PE2005000245 A PE 2005000245A PE 2005000245 A PE2005000245 A PE 2005000245A PE 20060074 A1 PE20060074 A1 PE 20060074A1
Authority
PE
Peru
Prior art keywords
alkyl
indol
methyl
tetrahydropyran
chloro
Prior art date
Application number
PE2005000245A
Other languages
English (en)
Inventor
Julia Adam-Worrall
Angus John Morrison
Takao Kiyoi
Duncan Robert Mcarthur
Grant Wishart
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of PE20060074A1 publication Critical patent/PE20060074A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A COMPUESTOS (INDOL-3-IL)-HETEROCICLO DE FORMULA I DONDE A ES ANILLO HETEROCICLICO DE 5 MIEMBROS; X1, X2, Y X3 SON CADA UNO N, O, S Y CR; R ES H, ALQUILO C1-C4, ENTRE OTROS; R1 ES ANILLO CARBOCICLICO DE 5-8 MIEMBROS, R2 ES H, CH3, CH2-CH3, ENTRE OTROS; R3 Y R4 SON CADA UNO H, ALQUIL C1-C6, CICLOALQUILO C3-C7, ENTRE OTROS; R5 ES H, ALQUILO C1-C4, ENTRE OTROS; R5' ES H, ALQUILO C1-C4; R6 ES H, ALQUILO C1-C4, ALQUILOXI C1-C4, ENTRE OTROS; R7 ES H, CN, HALOGENO, ENTRE OTROS. SON PREFERIDOS: 7-CLORO-3-(5-{[N-ETIL-N-(2-METOXIETIL)AMINO]METIL}-[1,2,4]-TIADIAZOL-3-IL)-1-(TETRAHIDROPIRAN-4-IL)METIL-1H-INDOL; 7-CLORO-3-{5-[(2,2-DIMETIL-PIRROLIDIN-1-IL)METIL]-[1,2,4]OXADIAZOL-3-IL}-1-(TETRAHIDROPIRAN-4-IL)METIL-1H-INDOL; ENTRE OTROS. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR DE CANNABINOIDES CB1 UTILES EN EL TRATAMIENTO DEL DOLOR CRONICO, NEUROPATICO, DE CANCER, ENTRE OTROS
PE2005000245A 2004-03-05 2005-03-04 Derivados de (indol-3-il)-heterociclos PE20060074A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04100902 2004-03-05
EP04103901 2004-08-12

Publications (1)

Publication Number Publication Date
PE20060074A1 true PE20060074A1 (es) 2006-02-18

Family

ID=36608981

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000245A PE20060074A1 (es) 2004-03-05 2005-03-04 Derivados de (indol-3-il)-heterociclos

Country Status (20)

Country Link
US (1) US7700634B2 (es)
EP (1) EP1725232B1 (es)
JP (1) JP5011097B2 (es)
AR (1) AR048745A1 (es)
AT (1) ATE384525T1 (es)
AU (1) AU2005224041B2 (es)
BR (1) BRPI0508404A (es)
CA (1) CA2557054C (es)
DE (1) DE602005004515T2 (es)
DK (1) DK1725232T3 (es)
ES (1) ES2300995T3 (es)
MY (1) MY139070A (es)
NZ (1) NZ549386A (es)
PE (1) PE20060074A1 (es)
PL (1) PL1725232T3 (es)
PT (1) PT1725232E (es)
RS (1) RS20060502A (es)
SI (1) SI1725232T1 (es)
TW (1) TWI330635B (es)
WO (1) WO2005089754A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI330635B (en) 2004-03-05 2010-09-21 Organon Nv (indol-3-yl)-heterocycle derivatives
TW200745096A (en) * 2005-08-23 2007-12-16 Organon Nv Indole derivatives
US7763732B2 (en) 2005-08-24 2010-07-27 N.V. Organon Indole derivatives
GB0614062D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
GB0614066D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
TW200848417A (en) * 2007-02-22 2008-12-16 Organon Nv Indole derivatives
AU2017260706B2 (en) 2016-05-04 2023-05-11 Inmed Pharmaceuticals Inc. Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
WO2019056123A1 (en) 2017-09-22 2019-03-28 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN
WO2022128050A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammation and pain
WO2025090587A1 (en) 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Cannabinoids compounds and their use in the treatment of neuronal disorders
WO2025090133A1 (en) 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Compositions and methods for use of cannabinol compounds in neuroprotection

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
US4939138A (en) 1988-12-29 1990-07-03 Sterling Drug Inc. 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo(1,2,3-DE)-1,4-benzoxazines
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
AUPR118000A0 (en) 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
EP1363632B1 (en) 2001-01-29 2010-08-25 The University of Connecticut Receptor selective cannabimimetic aminoalkylindoles
TW200402417A (en) 2002-06-21 2004-02-16 Akzo Nobel Nv 1-[(Indol-3-yl)carbonyl]piperazine derivatives
BRPI0417626A (pt) 2003-12-17 2007-03-27 Akzo Nobel Nv derivado de 1-[(indol-3-il) carbonil] piperazina tricìclica, composição farmacêutica, uso de um derivado de 1-[(indol-3-il) carbonil] piperazina tricìclica
TWI330635B (en) 2004-03-05 2010-09-21 Organon Nv (indol-3-yl)-heterocycle derivatives
TW200745096A (en) 2005-08-23 2007-12-16 Organon Nv Indole derivatives
US7763732B2 (en) * 2005-08-24 2010-07-27 N.V. Organon Indole derivatives
TW200848417A (en) 2007-02-22 2008-12-16 Organon Nv Indole derivatives

Also Published As

Publication number Publication date
ATE384525T1 (de) 2008-02-15
DK1725232T3 (da) 2008-05-26
CA2557054A1 (en) 2005-09-29
WO2005089754A1 (en) 2005-09-29
TWI330635B (en) 2010-09-21
MY139070A (en) 2009-08-28
EP1725232A1 (en) 2006-11-29
AU2005224041B2 (en) 2011-03-10
JP2007526281A (ja) 2007-09-13
BRPI0508404A (pt) 2007-07-17
CA2557054C (en) 2013-02-19
AU2005224041A1 (en) 2005-09-29
US20070142446A1 (en) 2007-06-21
ES2300995T3 (es) 2008-06-16
PL1725232T3 (pl) 2008-07-31
EP1725232B1 (en) 2008-01-23
DE602005004515T2 (de) 2009-01-29
TW200602316A (en) 2006-01-16
DE602005004515D1 (de) 2008-03-13
PT1725232E (pt) 2008-03-04
US7700634B2 (en) 2010-04-20
RS20060502A (sr) 2008-11-28
JP5011097B2 (ja) 2012-08-29
NZ549386A (en) 2009-12-24
AR048745A1 (es) 2006-05-24
SI1725232T1 (sl) 2008-06-30

Similar Documents

Publication Publication Date Title
RU2010151410A (ru) Производные аминодигидротиазина
PE20060074A1 (es) Derivados de (indol-3-il)-heterociclos
TR200100378T2 (tr) P-maddesi aşırısının aracılık ettiği hastalıkların tedavisindeki ilaç
PE20081557A1 (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
DE60025189D1 (de) Cyanopyrrole als progesteronrezeptoragonisten
PE108898A1 (es) Derivados 6,5-heterobiciclicos sustituidos
AR059178A1 (es) Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer.
HUP0303652A2 (hu) Ciklikus származékok, mint kemokin receptor aktivitás modulátorai és ezeket tartalmazó gyógyszerkészítmények
PE20091371A1 (es) Inhibidores de hsp90
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
UY25873A1 (es) Derivados de 3-azabiciclo [3.1.0] hexano útiles en terapia en afecciones mediadas por receptores opiáceos
HUP0301573A2 (hu) Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PE41796A1 (es) Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c.
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
PE20010931A1 (es) Oxazolidinonas que tienen la funcion de una sulfoximina
MA28422B1 (fr) Derives de n- (1,5-diphenyl-1h-pyrazol-3-yl) sulfonamide avec une affinite pour les recepteurs cb1
ATE433454T1 (de) Pyrazoloä1,5-aüpyrimidine als antagonisten des adenosin-a2a-rezeptors
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
TR200402529T4 (tr) Yeni Fenalliloksi fenil türevleri.
PE20090112A1 (es) Derivados de indol como agonistas del receptor de canabinoides cb1
PE20080941A1 (es) Compuestos triciclicos como agonistas del receptor de melatonina
PE20010389A1 (es) Combinacion de un agonista del receptor 5ht1, cafeina, un inhibidor de la cox-2 y su uso para el tratamiento de la migrana
PE20061351A1 (es) COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38

Legal Events

Date Code Title Description
FC Refusal